A bright future ahead or early warning signs?

It’s time for another update on the KRAS and SHP2 niches… it seems this space is much faster moving than our previous quarterly rolling updates in the past on other areas such as T70M in EGFR mutant lung cancers, checkpoint blockade in NSCLC, or new developments in CAR-T or CLL/iNHL.

It’s a sign of the modern times.

There’s always new entrants, new science and new clinical data to learn more about so without much further ado, let’s roll…

To learn more about our ongoing reporting on the KRAS niche to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by